Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LepVax
- Development stage
- Phase 2
- Lead developer
- American Leprosy Missions
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
**LepVax** is an investigational, adjuvanted recombinant protein-subunit vaccine for prevention of leprosy and potential adjunctive immunotherapy in people with leprosy. It contains LEP-F1, an approximately 89-kDa tetravalent fusion protein comprising *Mycobacterium leprae* antigens ML2531, ML2380, ML2055, and ML2028, formulated with GLA-SE, a stable oil-in-water emulsion containing the synthetic Toll-like receptor 4 agonist glucopyranosyl lipid adjuvant. The antigen component is intended to induce antigen-specific cellular and humoral immunity against *M. leprae*, while GLA-SE promotes innate immune activation and a T helper 1-biased adaptive response. It completed first-in-human Phase 1 testing in healthy US adults and has advanced to Phase 1b/2a clinical development in Brazil. ([nature.com](https://www.nature.com/articles/s41541-018-0050-z))
- Brand names
- LepVax
- Other names
- LEP-F1 + GLA-SELepVax
02
Targets
Ag85B (Antigen 85B)M. leprae (Mycobacterium leprae)EsxR (ESAT-6-like protein EsxR)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on LepVax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LepVax.